Fletcher C - Search Results

1

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.

Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Among authors: fletcher c. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.

2

Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.

Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B. Moyle G, et al. Among authors: fletcher c. HIV Med. 2006 May;7(4):243-7. doi: 10.1111/j.1468-1293.2006.00363.x. HIV Med. 2006. PMID: 16630036 Free article.

3

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B. Boffito M, et al. Among authors: fletcher c. AIDS. 2007 Jul 11;21(11):1449-55. doi: 10.1097/QAD.0b013e3282170ab1. AIDS. 2007. PMID: 17589191

4

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Winston A, Pozniak A, Smith N, Fletcher C, Mandalia S, Parmar D, Gibbons S, Back D, Gazzard B, Nelson M. Winston A, et al. Among authors: fletcher c. AIDS. 2004 Feb 20;18(3):572-4. doi: 10.1097/00002030-200402200-00029. AIDS. 2004. PMID: 15090815 Clinical Trial.

5

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Boffito M, et al. Among authors: fletcher c. Antivir Ther. 2004 Jun;9(3):423-9. Antivir Ther. 2004. PMID: 15259905 Clinical Trial.

6

Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19.

Arber N, Shah PL, Assoumou L, Rokx C, De Castro N, Bakhai A, Soriano Viladomiu A, Mateu L, Lumbreras C, Estrada V, Curran A, Sellier PO, Duffy A, Fletcher C, Mozaffari E, Haubrich R, Hodgkins P, Pozniak A, Raffi F. Arber N, et al. Among authors: fletcher c. Infect Dis Now. 2023 Oct;53(7):104760. doi: 10.1016/j.idnow.2023.104760. Epub 2023 Jul 14. Infect Dis Now. 2023. PMID: 37454762

7

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A. Boffito M, et al. Among authors: fletcher c. J Antimicrob Chemother. 2005 Apr;55(4):542-5. doi: 10.1093/jac/dki043. Epub 2005 Feb 18. J Antimicrob Chemother. 2005. PMID: 15722388

8

Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Gazzard B, Pozniak A. Boffito M, et al. Among authors: fletcher c. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84. doi: 10.1097/01.qai.0000136060.65716.1a. J Acquir Immune Defic Syndr. 2004. PMID: 15483467

9

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M. Winston A, et al. Among authors: fletcher c. AIDS. 2006 Jun 26;20(10):1401-6. doi: 10.1097/01.aids.0000233573.41597.8a. AIDS. 2006. PMID: 16791014

10

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A. Boffito M, et al. Among authors: fletcher c. AIDS Res Hum Retroviruses. 2006 Aug;22(8):749-56. doi: 10.1089/aid.2006.22.749. AIDS Res Hum Retroviruses. 2006. PMID: 16910830

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,606 results

Search Page